Cavan Redmond named president of Wyeth Consumer Healthcare
MADISON, N.J. As part of a series of executive promotions announced Friday morning, Wyeth named Cavan Redmond president of its Wyeth Consumer Healthcare effective Dec. 1.
Redmond, 46, will be responsible for the division’s global operations. The company also announced that Douglas Rogers, 47, has been named to the position of president, U.S. and global new business, Wyeth Consumer Healthcare.
“Under Cavan’s leadership, Wyeth has become the third largest biotech company in the world. We know he’ll bring the same formula for success to our consumer brands,” stated Bernard Poussot, Wyeth president and chief operating officer. “In addition, Doug’s marketing and commercial skills, coupled with his in-depth knowledge, energy and experience, will serve as a tremendous advantage for the division.”
Redmond has been serving as executive vice president and general manager of the BioPharma business unit of Wyeth Pharmaceuticals. He also has held positions of increasing responsibility in the commercial and R&D organizations. Prior to joining Wyeth Pharmaceuticals, Redmond worked at Sandoz both in the United States and in Switzerland. He earned a bachelor’s degree in political science from the University of Maryland and a master’s degree in administration from The Johns Hopkins University. He also completed a post-graduate fellowship in organizational change management.
Most recently, Rogers served as president, Wyeth Consumer Healthcare, and prior to that, he served as president, Wyeth Consumer Healthcare, U.S. He joined Wyeth in November 1994 with the acquisition of American Cyanamid, where he was vice president of marketing for Lederle Consumer Health. Before that, he held various sales and marketing positions for Lederle Pharmaceuticals, Lederle Consumer Health, American Home Foods and Wyeth Consumer Healthcare. He holds a Bachelor’s degree in journalism and an M.B.A., both from Lehigh University.
Jason Ash named PacificHealth president and CEO
MATAWAN, N.J. PacificHealth Laboratories on Thursday named Jason Ash as the company’s president and chief operating officer, as well as a member of the company’s board, effective Jan. 3.
Ash assumes the role of president from Portman, who will continue to serve as chief executive officer, chief scientific officer and chairman.
“Jason brings a great deal of knowledge and experience in the performance beverage arena, and actually led Cadbury’s negotiations leading to their acquisition of the Accelerade and Endurox trade marks and intellectual property,” Portman stated. “Jason’s existing knowledge of our company and our growth objectives will enable him to hit the ground running and provides an excellent opportunity for PacificHealth to rapidly expand upon our existing growth strategy.”
Ash also assumes chief operating officer duties currently held by Stephen Kuchen, who will continue to serve as chief financial officer, treasurer, secretary and director.
Ash brings a decade worth of experience in commercial brand management and consumer marketing to PacificHealth, most recently serving as general manager and vice president of Cadbury Schweppes Americas Beverages Sports in the energy and water category unit.
Next announces results of Nexrutine dietary supplement study
SALINAS, Calif. Next Pharmaceuticals announced Thursday the results of a clinical study on Nexrutine, conducted at The LaValle Metabolic Institute in Cincinnati.
The study concluded that Nexrutine, when used as a dietary supplement, helps in the management of pain and/or inflammation and helps promote a restful sleep with minimal side effects.
“Suffering from pain and inflammation can be a life-changing challenge,” stated Jim LaValle, founder of The LaValle Metabolic Institute and author of many books, including Cracking the Metabolic Code and the Cox-2 Connection. “Many of our patients are relieved to find a natural remedy that is not only cardio protective, but unlike aspirin, is easy on the stomach. This study demonstrates that Nexrutine has an excellent safety profile.”
Out of the 401 participants in the study, 92 percent reported Nexrutine provided pain relief and 93 percent reported improvement in their overall condition.
Nexrutine is a proprietary blend of natural ingredients developed to address general aches and pains associated with physical activity and over-exertion.
The clinical trial was designed to be an open label, single center, clinical trial.